# Xeris Biopharma Holdings, Inc.: financial statements, quarterly

XERS · Nasdaq · CIK 1867096 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xers.md) · [Financials](/companies/xers/financials.md) · [Filings](/companies/xers/filings.md) · [Insiders](/companies/xers/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xers/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [48.3](/filings/0001867096-24-000187.md) | [44.4 d](/filings/0001867096-26-000016.md) | [40.6](/filings/0001867096-25-000089.md) | [48.1](/filings/0001867096-25-000136.md) | [54.3](/filings/0001867096-25-000159.md) | [60.1 d](/filings/0001867096-26-000016.md) | [60.1](/filings/0001867096-26-000030.md) | [71.5](/filings/0001867096-26-000065.md) | [74.4](/filings/0001867096-25-000159.md) | [85.8 d](/filings/0001867096-26-000016.md) | [83.1](/filings/0001867096-26-000030.md) | [92.1](/filings/0001867096-26-000065.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [5.0](/filings/0001867096-24-000187.md) | [6.4 d](/filings/0001867096-26-000016.md) | [7.8](/filings/0001867096-25-000089.md) | [5.8](/filings/0001867096-25-000136.md) | [5.9](/filings/0001867096-25-000159.md) | [6.1 d](/filings/0001867096-26-000016.md) | [7.8](/filings/0001867096-26-000030.md) | [8.1](/filings/0001867096-26-000065.md) | [7.5](/filings/0001867096-25-000159.md) | [7.9 d](/filings/0001867096-26-000016.md) | [8.8](/filings/0001867096-26-000030.md) | [10.7](/filings/0001867096-26-000065.md) |
| Selling, general and administrative | $m | [37.3](/filings/0001867096-24-000187.md) | [37.6 d](/filings/0001867096-26-000016.md) | [38.4](/filings/0001867096-25-000089.md) | [40.0](/filings/0001867096-25-000136.md) | [45.0](/filings/0001867096-25-000159.md) | [40.1 d](/filings/0001867096-26-000016.md) | [44.0](/filings/0001867096-26-000030.md) | [44.4](/filings/0001867096-26-000065.md) | [46.5](/filings/0001867096-25-000159.md) | [47.5 d](/filings/0001867096-26-000016.md) | [53.1](/filings/0001867096-26-000030.md) | [61.0](/filings/0001867096-26-000065.md) |
| Operating income | $m | [(4.9)](/filings/0001867096-24-000187.md) | [(9.8) d](/filings/0001867096-26-000016.md) | [(14.2)](/filings/0001867096-25-000089.md) | [(8.2)](/filings/0001867096-25-000136.md) | [(12.9)](/filings/0001867096-25-000159.md) | [1.7 d](/filings/0001867096-26-000016.md) | [(3.1)](/filings/0001867096-26-000030.md) | [4.5](/filings/0001867096-26-000065.md) | [6.7](/filings/0001867096-25-000159.md) | [16.8 d](/filings/0001867096-26-000016.md) | [7.9](/filings/0001867096-26-000030.md) | [5.2](/filings/0001867096-26-000065.md) |
| Interest expense | $m | [6.8](/filings/0001867096-23-000139.md) | [7.0 d](/filings/0001867096-24-000031.md) | [7.0](/filings/0001867096-24-000065.md) | [8.0](/filings/0001867096-25-000136.md) | [7.8](/filings/0001867096-25-000159.md) | [7.7 d](/filings/0001867096-26-000016.md) | [7.3](/filings/0001867096-26-000030.md) | [7.4](/filings/0001867096-26-000065.md) | [7.3](/filings/0001867096-25-000159.md) | [7.2 d](/filings/0001867096-26-000016.md) | [6.9](/filings/0001867096-26-000030.md) | [6.9](/filings/0001867096-26-000065.md) |
| Income tax | $m | [(0.3)](/filings/0001867096-24-000187.md) | [(0.2) d](/filings/0001867096-26-000016.md) | [0.3](/filings/0001867096-25-000089.md) | [0.7](/filings/0001867096-25-000136.md) | [(3.3)](/filings/0001867096-25-000159.md) | [0.0 d](/filings/0001867096-26-000016.md) | [0.0](/filings/0001867096-26-000030.md) | [0.0](/filings/0001867096-26-000065.md) | [0.0](/filings/0001867096-25-000159.md) | [0.0 d](/filings/0001867096-26-000016.md) | [0.0](/filings/0001867096-26-000030.md) | [0.0](/filings/0001867096-26-000065.md) |
| Net income | $m | [(12.2)](/filings/0001867096-24-000187.md) | [(13.4) d](/filings/0001867096-26-000016.md) | [(19.0)](/filings/0001867096-25-000159.md) | [(15.0)](/filings/0001867096-25-000159.md) | [(15.7)](/filings/0001867096-25-000159.md) | [(5.1) d](/filings/0001867096-26-000016.md) | [(9.2)](/filings/0001867096-26-000065.md) | [(1.9)](/filings/0001867096-26-000065.md) | [0.6](/filings/0001867096-25-000159.md) | [11.1 d](/filings/0001867096-26-000016.md) | [2.2](/filings/0001867096-26-000065.md) | [(31.1)](/filings/0001867096-26-000065.md) |
| Diluted EPS | $ per share | [(0.09)](/filings/0001867096-24-000187.md) | not reported | [(0.14)](/filings/0001867096-25-000089.md) | [(0.10)](/filings/0001867096-25-000136.md) | [(0.11)](/filings/0001867096-25-000159.md) | not reported | [(0.06)](/filings/0001867096-26-000030.md) | [(0.01)](/filings/0001867096-26-000065.md) | [0.00](/filings/0001867096-25-000159.md) | not reported | [0.01](/filings/0001867096-26-000030.md) | [(0.18)](/filings/0001867096-26-000065.md) |
| Basic EPS | $ per share | [(0.09)](/filings/0001867096-24-000187.md) | not reported | [(0.14)](/filings/0001867096-25-000089.md) | [(0.10)](/filings/0001867096-25-000136.md) | [(0.11)](/filings/0001867096-25-000159.md) | not reported | [(0.06)](/filings/0001867096-26-000030.md) | [(0.01)](/filings/0001867096-26-000065.md) | [0.00](/filings/0001867096-25-000159.md) | not reported | [0.01](/filings/0001867096-26-000030.md) | [(0.18)](/filings/0001867096-26-000065.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [46.1](/filings/0001867096-24-000187.md) | [67.4](/filings/0001867096-26-000016.md) | [62.7](/filings/0001867096-25-000089.md) | [57.6](/filings/0001867096-25-000136.md) | [59.2](/filings/0001867096-25-000159.md) | [71.6](/filings/0001867096-26-000016.md) | [58.4](/filings/0001867096-26-000030.md) | [59.3](/filings/0001867096-26-000065.md) | [91.6](/filings/0001867096-25-000159.md) | [111](/filings/0001867096-26-000065.md) | [112](/filings/0001867096-26-000030.md) | [122](/filings/0001867096-26-000065.md) |
| Current assets | $m | [158](/filings/0001867096-23-000139.md) | [156](/filings/0001867096-25-000039.md) | [173](/filings/0001867096-24-000065.md) | [170](/filings/0001867096-24-000162.md) | [163](/filings/0001867096-24-000187.md) | [168](/filings/0001867096-26-000016.md) | [163](/filings/0001867096-25-000089.md) | [186](/filings/0001867096-25-000136.md) | [224](/filings/0001867096-25-000159.md) | [240](/filings/0001867096-26-000065.md) | [252](/filings/0001867096-26-000030.md) | [275](/filings/0001867096-26-000065.md) |
| Total assets | $m | [328](/filings/0001867096-23-000139.md) | [323](/filings/0001867096-25-000039.md) | [337](/filings/0001867096-24-000065.md) | [332](/filings/0001867096-24-000162.md) | [321](/filings/0001867096-24-000187.md) | [323](/filings/0001867096-26-000016.md) | [315](/filings/0001867096-25-000089.md) | [335](/filings/0001867096-25-000136.md) | [370](/filings/0001867096-25-000159.md) | [384](/filings/0001867096-26-000065.md) | [392](/filings/0001867096-26-000030.md) | [412](/filings/0001867096-26-000065.md) |
| Current liabilities | $m | [87.0](/filings/0001867096-23-000139.md) | [95.2](/filings/0001867096-25-000039.md) | [73.1](/filings/0001867096-24-000065.md) | [75.5](/filings/0001867096-24-000162.md) | [91.0](/filings/0001867096-24-000187.md) | [100](/filings/0001867096-26-000016.md) | [95.1](/filings/0001867096-25-000089.md) | [95.2](/filings/0001867096-25-000136.md) | [116](/filings/0001867096-25-000159.md) | [110](/filings/0001867096-26-000065.md) | [119](/filings/0001867096-26-000030.md) | [190](/filings/0001867096-26-000065.md) |
| Total liabilities | $m | [324](/filings/0001867096-23-000139.md) | [329](/filings/0001867096-25-000039.md) | [346](/filings/0001867096-24-000065.md) | [351](/filings/0001867096-24-000162.md) | [349](/filings/0001867096-24-000187.md) | [353](/filings/0001867096-26-000016.md) | [351](/filings/0001867096-25-000089.md) | [354](/filings/0001867096-25-000136.md) | [371](/filings/0001867096-25-000159.md) | [370](/filings/0001867096-26-000065.md) | [379](/filings/0001867096-26-000030.md) | [422](/filings/0001867096-26-000065.md) |
| Long-term debt | $m | [190](/filings/0001867096-23-000139.md) | [191](/filings/0001867096-25-000039.md) | [230](/filings/0001867096-24-000065.md) | [230](/filings/0001867096-24-000162.md) | [216](/filings/0001867096-24-000187.md) | [217](/filings/0001867096-26-000016.md) | [218](/filings/0001867096-25-000089.md) | [219](/filings/0001867096-25-000136.md) | [219](/filings/0001867096-25-000159.md) | [220](/filings/0001867096-26-000065.md) | [221](/filings/0001867096-26-000030.md) | [189](/filings/0001867096-26-000065.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0001867096-25-000039.md) | not reported | not reported | [15.1](/filings/0001867096-24-000187.md) | [15.1](/filings/0001867096-26-000016.md) | [12.0](/filings/0001867096-25-000089.md) | [0.0](/filings/0001867096-25-000136.md) | [0.0](/filings/0001867096-25-000159.md) | [0.0](/filings/0001867096-26-000065.md) | not reported | [63.8](/filings/0001867096-26-000065.md) |
| Shareholders' equity | $m | [3.9](/filings/0001867096-24-000187.md) | [(6.8)](/filings/0001867096-26-000016.md) | [(9.2)](/filings/0001867096-25-000159.md) | [(19.3)](/filings/0001867096-25-000159.md) | [(28.3)](/filings/0001867096-25-000159.md) | [(29.6)](/filings/0001867096-26-000065.md) | [(35.1)](/filings/0001867096-26-000065.md) | [(19.3)](/filings/0001867096-26-000065.md) | [(0.9)](/filings/0001867096-25-000159.md) | [13.7](/filings/0001867096-26-000065.md) | [13.0](/filings/0001867096-26-000065.md) | [(9.7)](/filings/0001867096-26-000065.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(14.6) d](/filings/0001867096-24-000187.md) | [7.5 d](/filings/0001867096-26-000016.md) | [(20.3)](/filings/0001867096-25-000089.md) | [(10.3) d](/filings/0001867096-25-000136.md) | [(8.3) d](/filings/0001867096-25-000159.md) | [2.0 d](/filings/0001867096-26-000016.md) | [(10.0)](/filings/0001867096-26-000030.md) | [0.2 d](/filings/0001867096-26-000065.md) | [18.4 d](/filings/0001867096-25-000159.md) | [20.0 d](/filings/0001867096-26-000016.md) | [9.9](/filings/0001867096-26-000030.md) | [8.3 d](/filings/0001867096-26-000065.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q4 FY2023 (2023-03-31) | Q4 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [136](/filings/0001867096-23-000139.md) | [137](/filings/0001867096-24-000065.md) | [137](/filings/0001867096-24-000162.md) | [138](/filings/0001867096-24-000187.md) | [141](/filings/0001867096-25-000089.md) | [148](/filings/0001867096-25-000136.md) | [149](/filings/0001867096-25-000159.md) | [152](/filings/0001867096-26-000030.md) | [159](/filings/0001867096-26-000065.md) | [178](/filings/0001867096-25-000159.md) | [178](/filings/0001867096-26-000030.md) | [173](/filings/0001867096-26-000065.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 182,320,306 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001867096-26-000065.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.